Nebula Genomics, a startup spun out of a Harvard Medical School laboratory in 2018, has signed an agreement today with EMD Serono (the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the U.S. and Canada) to allow access of genomic data from Nebula’s blockchain-based network.

According to a recent Nebula blog post, the goal of this pilot project is to help EMD Serono enhance research efforts by supporting its scientists as they develop potential new medicines. Access to Nebula’s database of anonymized genomic data will help researchers better understand the causes of diseases.